Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aim of trial is to reduce virologic relapse rate for patients who have completed the standard combination therapy
Subscribe to our email newsletter
Amarillo (ABI) and CytoPharm have started the enrollment for a study of ABI’s oral interferon-alpha lozenges, for chronic hepatitis-C virus infection.
The aim of the trial is to reduce the virologic relapse rate for patients who have completed the standard combination therapy, which consists of high dose injectable interferon-alpha and Ribavirin. Although most patients respond to the standard therapy, up to 50% of those with certain high-risk viral genotypes relapse after treatment.
In this study, a total of 165 patients who test positive for a high-risk hepatitis C viral genotype, will receive one of two different doses of human interferon-alpha or placebo given daily for 24 weeks. Full study enrollment is expected to complete by the end of the year.
The companies announced that CytoPharm is planning a study of oral interferon lozenges in the treatment of influenza, which is to be launched during the 2009/2010 flu season in Taiwan.